SEC Tracker
Get the app
Person · CIK 1754371

Jennifer E. Cook

Director at Jazz Pharmaceuticals, BridgeBio Pharma and Denali Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$22.5M
Noticed on Form 144$23.9M
Bought on Form 4$0
Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Jazz Pharmaceuticals JAZZOrdinary SharesDirectly10,736Aug 31, 2026 · Filing · EDGAR
Jazz Pharmaceuticals JAZZNon-Qualified Stock Option (right to buy)
exercise $170.74, expires Feb 24, 2031, into Ordinary Shares
Directly6,475Feb 25, 2021 · Filing · EDGAR
BridgeBio Pharma BBIOCommon StockDirectly8,383Jul 9, 2026 · Filing · EDGAR
Denali Therapeutics DNLICommon StockDirectly32,483Jun 3, 2026 · Filing · EDGAR
Denali Therapeutics DNLIStock Option (right to buy)
exercise $19.66, expires Jun 3, 2036, into Common Stock
Directly19,226Jun 3, 2026 · Filing · EDGAR

Sold and noticed by quarter

Jennifer E. Cook: dollars sold on Form 4 and noticed on Form 144 per quarter, Q4 2021 to Q4 2026$14M$0Q4 2021: notice not machine-readableQ4 2021: $51K sold on Form 4Q1 2022: $0 noticed on Form 144Q1 2022: $0 sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: notice not machine-readableQ3 2022: $166K sold on Form 4Q4 2022: notice not machine-readableQ4 2022: $65K sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $346K noticed on Form 144Q3 2023: $171K sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $50K sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $32K noticed on Form 144Q2 2024: $32K sold on Form 4Q3 2024: $341K noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $418K noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $8.8M noticed on Form 144Q2 2026: $8.8M sold on Form 4Q3 2026: $14M noticed on Form 144Q3 2026: $13.2M sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q4 2021Q1 2023Q2 2024Q3 2025Q4 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q3 2026$13.2M$14M
Q2 2026$8.8M$8.8M
Q3 2025—$418K
Q3 2024—$341K
Q2 2024$32K$32K
Q4 2023$50K—
Q3 2023$171K$346K
Q4 2022$65KNot machine-readable
Q3 2022$166KNot machine-readable
Q4 2021$51KNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Jazz Pharmaceuticals JAZZ · Etrade Financial · No 10b5-1 plan stated · 4 notices
Aug 31, 20263,507 · ~$858KAug 31, 2026Not sold yetFiling · EDGAR
Aug 8, 20253,731 · ~$418KAug 8, 2025Not sold within 90 daysFiling · EDGAR
Aug 5, 20243,075 · ~$341KAug 6, 2024Not sold within 90 daysFiling · EDGAR
Aug 14, 20232,561 · ~$346KAug 14, 2023Partly sold Sold 1,241 at $138.16 on Aug 14 · $171K likely match Form 4Filing · EDGAR
BridgeBio Pharma BBIO · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 16, 2026 · 4 notices
Jul 9, 2026148,589 · ~$13.2MJul 9, 2026Sold as noticed Sold 148,589 in 2 sales, Jul 9 to Jul 9 · $13.2M Form 4Filing · EDGAR
Jun 24, 202637,167 · ~$2.6MJun 24, 2026Sold as noticed Sold 37,167 at $70.00 on Jun 24 · $2.6M Form 4Filing · EDGAR
Jun 23, 20262,196 · ~$151KJun 23, 2026Sold as noticed Sold 2,196 at $68.57 on Jun 23 · $151K Form 4Filing · EDGAR
Jun 15, 202690,240 · ~$6MJun 15, 2026Sold as noticed Sold 90,240 in 2 sales, Jun 15 to Jun 15 · $6M Form 4Filing · EDGAR
Denali Therapeutics DNLI · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 7, 2024 · 1 notice
Jun 6, 20241,458 · ~$32KJun 6, 2024Sold as noticed Sold 1,458 at $21.73 on Jun 6 · $32K Form 4Filing · EDGAR
Sales without a matching Form 144 · 4 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Jazz Pharmaceuticals (JAZZ): Sold 417 at $119.27 on Dec 4, 2023 · $50KFiling · EDGAR
———Notice not machine-readable Jazz Pharmaceuticals (JAZZ): Sold 420 at $154.68 on Dec 2, 2022 · $65KFiling · EDGAR
———Notice not machine-readable Jazz Pharmaceuticals (JAZZ): Sold 1,089 at $152.32 on Aug 8, 2022 · $166KFiling · EDGAR
———Notice not machine-readable Jazz Pharmaceuticals (JAZZ): Sold 417 at $121.30 on Dec 2, 2021 · $51KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Jazz Pharmaceuticals JAZZ Director · filings 2020 to 2026 · sold $503K · $2M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Aug 31, 2026Shares withheld for tax or exercise price−14$244.06$3K12,428 directFiling · EDGAR
Aug 31, 2026Shares withheld for tax or exercise price−1,692$241.39$408K10,736 directFiling · EDGAR
Aug 5, 2026Grant or award from the company+1,60512,442 directFiling · EDGAR
Aug 8, 2025Shares withheld for tax or exercise price−1,805$111.25$201K10,837 directFiling · EDGAR
Aug 7, 2025Grant or award from the company+3,50712,642 directFiling · EDGAR
Aug 6, 2024Shares withheld for tax or exercise price−1,484$111.35$165K9,135 directFiling · EDGAR
Aug 2, 2024Grant or award from the company+3,73110,619 directFiling · EDGAR
Dec 4, 2023Open-market or private sale−417$119.27$50K6,888 directFiling · EDGAR
Aug 14, 2023Open-market or private sale−1,241$138.16$171K7,305 directFiling · EDGAR
Aug 11, 2023Grant or award from the company+3,0758,546 directFiling · EDGAR
Dec 2, 2022Open-market or private sale−420$154.68$65K5,471 directFiling · EDGAR
Aug 8, 2022Open-market or private sale−1,089$152.32$166K5,891 directFiling · EDGAR
Aug 5, 2022Grant or award from the company+2,5616,980 directFiling · EDGAR
Dec 2, 2021Open-market or private sale−417$121.30$51K4,419 directFiling · EDGAR
Jul 29, 2021Grant or award from the company+2,2464,836 directFiling · EDGAR
Feb 25, 2021Grant or award from the company+2,5902,590 directFiling · EDGAR
Feb 25, 2021Grant or award from the company
Non-Qualified Stock Option (right to buy)
+6,4756,475 directFiling · EDGAR

BridgeBio Pharma BBIO Director · filings 2019 to 2026 · sold $21.9M · $21.9M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jul 9, 2026Option or RSU exercised or converted+19,000$8.45$161K27,383 directFiling · EDGAR
Jul 9, 2026Option or RSU exercised or converted+112,422$29.00$3.3M139,805 directFiling · EDGAR
Jul 9, 2026Option or RSU exercised or converted+17,167$16.75$288K156,972 directFiling · EDGAR
Jul 9, 2026Sale under a 10b5-1 plan−36,167$84.00$3M120,805 directFiling · EDGAR
Jul 9, 2026Sale under a 10b5-1 plan−112,422$90.00$10.1M8,383 directFiling · EDGAR
Jul 9, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−19,0000 directFiling · EDGAR
Jul 9, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−112,4220 directFiling · EDGAR
Jul 9, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−17,1670 directFiling · EDGAR
Jun 24, 2026Option or RSU exercised or converted+20,000$8.45$169K28,383 directFiling · EDGAR
Jun 24, 2026Option or RSU exercised or converted+17,167$16.75$288K45,550 directFiling · EDGAR
Jun 24, 2026Sale under a 10b5-1 plan−37,167$70.00$2.6M8,383 directFiling · EDGAR
Jun 24, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−20,00019,000 directFiling · EDGAR
Jun 24, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−17,16717,167 directFiling · EDGAR
Jun 23, 2026Sale under a 10b5-1 plan−2,196$68.57$151K8,383 directFiling · EDGAR
Jun 22, 2026Grant or award from the company+3,99010,579 directFiling · EDGAR
Jun 22, 2026Grant or award from the company
Stock Option (Right to Buy)
+5,2775,277 directFiling · EDGAR
Jun 15, 2026Option or RSU exercised or converted+65,921$8.45$557K79,662 directFiling · EDGAR
Jun 15, 2026Option or RSU exercised or converted+17,167$16.75$288K96,829 directFiling · EDGAR
Jun 15, 2026Sale under a 10b5-1 plan−88,737$66.62$5.9M8,092 directFiling · EDGAR
Jun 15, 2026Sale under a 10b5-1 plan−1,503$67.14$101K6,589 directFiling · EDGAR
Jun 15, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−65,92139,000 directFiling · EDGAR
Jun 15, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−17,16734,334 directFiling · EDGAR
Jun 20, 2025Grant or award from the company+6,58913,741 directFiling · EDGAR
Jun 20, 2025Grant or award from the company
Stock Option (Right to Buy)
+8,4258,425 directFiling · EDGAR
Jun 21, 2024Grant or award from the company
Stock Option (Right to Buy)
+26,01426,014 directFiling · EDGAR
Jun 21, 2023Grant or award from the company
Stock Option (right to buy)
+51,50151,501 directFiling · EDGAR
Jun 22, 2022Grant or award from the company
Stock Option (right to buy)
+104,921104,921 directFiling · EDGAR
Nov 16, 2021Option or RSU exercised or converted+3,5767,152 directFiling · EDGAR
Nov 16, 2021Option or RSU exercised or converted
Restricted Stock Units
−3,5760 directFiling · EDGAR
Jun 17, 2021Grant or award from the company
Stock Option (right to buy)
+38,89538,895 directFiling · EDGAR
Nov 16, 2020Option or RSU exercised or converted+3,5763,576 directFiling · EDGAR
Nov 16, 2020Option or RSU exercised or converted
Restricted Stock Units
−3,5763,576 directFiling · EDGAR
Jun 2, 2020Grant or award from the company
Stock Option (right to buy)
+112,422112,422 directFiling · EDGAR
Dec 12, 2019Grant or award from the company
Stock Option (right to buy)
+82,87882,878 directFiling · EDGAR

Denali Therapeutics DNLI Director · filings 2018 to 2026 · sold $32K · $32K noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jun 3, 2026Grant or award from the company+6,40832,483 directFiling · EDGAR
Jun 3, 2026Grant or award from the company
Stock Option (right to buy)
+19,22619,226 directFiling · EDGAR
Jun 3, 2025Grant or award from the company+6,03726,075 directFiling · EDGAR
Jun 3, 2025Grant or award from the company
Stock Option (right to buy)
+18,11118,111 directFiling · EDGAR
Jun 6, 2024Sale under a 10b5-1 plan−1,458$21.73$32K20,038 directFiling · EDGAR
May 31, 2024Grant or award from the company+5,96721,496 directFiling · EDGAR
May 31, 2024Grant or award from the company
Stock Option (right to buy)
+17,90117,901 directFiling · EDGAR
Jun 1, 2023Grant or award from the company+4,21615,529 directFiling · EDGAR
Jun 1, 2023Grant or award from the company
Stock Option (right to buy)
+12,64912,649 directFiling · EDGAR
Jun 2, 2022Grant or award from the company+5,98611,313 directFiling · EDGAR
Jun 2, 2022Grant or award from the company
Stock Option (right to buy)
+17,95917,959 directFiling · EDGAR
Jun 2, 2021Grant or award from the company+2,0745,327 directFiling · EDGAR
Jun 2, 2021Grant or award from the company
Stock Option (right to buy)
+6,2226,222 directFiling · EDGAR
Jun 1, 2021Option or RSU exercised or converted+3,2533,253 directFiling · EDGAR
Jun 1, 2021Option or RSU exercised or converted
Restricted Stock Units
−3,2530 directFiling · EDGAR
Jun 3, 2020Grant or award from the company
Stock Option (right to buy)
+15,18315,183 directFiling · EDGAR
Jun 3, 2020Grant or award from the company
Restricted Stock Units
+3,2533,253 directFiling · EDGAR
May 30, 2019Grant or award from the company
Stock Option (right to buy)
+27,24527,245 directFiling · EDGAR
Nov 6, 2018Grant or award from the company
Stock Option (right to buy)
+50,04450,044 directFiling · EDGAR
All 46 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Sep 2, 2026Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 31, 2026Form 144Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 7, 2026Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Jul 13, 2026Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jul 9, 2026Form 144BridgeBio Pharma BBIOFiling · EDGAR
Jun 24, 2026Form 144BridgeBio Pharma BBIOFiling · EDGAR
Jun 24, 2026Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 23, 2026Form 144BridgeBio Pharma BBIOFiling · EDGAR
Jun 17, 2026Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 15, 2026Form 144BridgeBio Pharma BBIOFiling · EDGAR
Jun 5, 2026Form 4Denali Therapeutics DNLIFiling · EDGAR
Aug 11, 2025Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 8, 2025Form 144Jazz Pharmaceuticals JAZZFiling · EDGAR
Jun 24, 2025Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 5, 2025Form 4Denali Therapeutics DNLIFiling · EDGAR
Aug 6, 2024Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 5, 2024Form 144Jazz Pharmaceuticals JAZZFiling · EDGAR
Jun 25, 2024Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 10, 2024Form 4Denali Therapeutics DNLIFiling · EDGAR
Jun 6, 2024Form 144Denali Therapeutics DNLIFiling · EDGAR
Jun 4, 2024Form 4Denali Therapeutics DNLIFiling · EDGAR
Dec 6, 2023Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 15, 2023Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 14, 2023Form 144Jazz Pharmaceuticals JAZZFiling · EDGAR
Jun 23, 2023Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 5, 2023Form 4Denali Therapeutics DNLIFiling · EDGAR
Feb 21, 2023Form 4BridgeBio Pharma BBIOFiling · EDGAR
Dec 6, 2022Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 9, 2022Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Jun 24, 2022Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 6, 2022Form 4Denali Therapeutics DNLIFiling · EDGAR
Dec 6, 2021Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Aug 2, 2021Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Jun 22, 2021Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 4, 2021Form 4Denali Therapeutics DNLIFiling · EDGAR
Jun 3, 2021Form 4Denali Therapeutics DNLIFiling · EDGAR
Mar 1, 2021Form 4Jazz Pharmaceuticals JAZZFiling · EDGAR
Dec 3, 2020Form 3Jazz Pharmaceuticals JAZZFiling · EDGAR
Nov 18, 2020Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 5, 2020Form 4Denali Therapeutics DNLIFiling · EDGAR
Jun 4, 2020Form 4BridgeBio Pharma BBIOFiling · EDGAR
Dec 16, 2019Form 4BridgeBio Pharma BBIOFiling · EDGAR
Dec 16, 2019Form 3BridgeBio Pharma BBIOFiling · EDGAR
May 31, 2019Form 4Denali Therapeutics DNLIFiling · EDGAR
Nov 8, 2018Form 4Denali Therapeutics DNLIFiling · EDGAR
Nov 8, 2018Form 3Denali Therapeutics DNLIFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.